All In Biotech

Drug Trial Radar · NCT03038399

Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

A 24-month Phase II Open-label, Multicenter Long-term Extension Study to Assess the Long-Term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Last checked: Nov 19, 2026Latest source record: May 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

46

Actual

Start

Feb 2, 2017

Primary completion

Apr 30, 2020

Study completion Apr 30, 2020

Sponsor

Lead sponsor
ReveraGen BioPharma, Inc.Industry
Sponsor type
Industry
Collaborators
University of Pittsburgh; Cooperative International Neuromuscular Research Group
First posted
Jan 31, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 4 years, up to 7 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This long-term extension study is an open-label, multiple-dose study to evaluate the long-term safety, tolerability, efficacy and PD of vamorolone administered once daily by liquid oral suspension over a Treatment Period of 24 months to young boys with DMD who participated in the VBP15-002 Phase IIa and VBP15-003 Phase IIa extension core studies.

Conditions

  • Duchenne Muscular Dystrophy

Interventions

  • Vamorolone 0.25 mg/day/dayDrug

    Oral administration of 0.25 mg/kg/day daily for 24 months.

  • Vamorolone 0.75 mg/day/dayDrug

    Oral administration of 0.75 mg/kg/day daily for 24 months.

  • Vamorolone 2.0 mg/day/dayDrug

    Oral administration of 2.0 mg/kg/day daily for 24 months.

  • Vamorolone 6.0 mg/day/dayDrug

    Oral administration of 6.0 mg/kg/day daily for 24 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE Version 4.03Time frame: 24 months
  2. Total Number of Adverse Events as Assessed by CTCAE Version 4.03Time frame: 24 Months

Locations

12 sites in 6 countries. Site status is shown where the registry gives one.

  • University of California Davis

    Davis, California

  • University of Florida

    Gainesville, Florida

  • Nemours Children's Hospital

    Orlando, Florida

  • Ann & Robert H. Lurie Children's Hospital

    Chicago, Illinois

  • Duke University

    Durham, North Carolina

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Royal Children's Hospital

    Melbourne, Australia

  • Sydney Children's Hospital

    Westmead, Australia

  • Alberta Children's Hospital

    Calgary, Alberta, Canada

  • Schneider Children's Medical Center

    Petah Tikva, Israel

  • Queen Silvia Children's Hospital

    Gothenburg, Sweden

  • Newcastle upon Tyne Hospitals NHS Foundation Trust

    Newcastle upon Tyne, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.